Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vivaxin vaccine for Plasmodium vivax malaria
NCT07172724Phase 1Not yet recruiting
- Sponsor
- Universidade Federal de Minas Gerais
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Vivaxin in Plasmodium vivax malaria (4 arms), sponsored by Universidade Federal de Minas Gerais. Primary endpoints: Safety and reactogenicity of adverse events (AE) in the first 14 days, Safety and reactogenicity of EA in the first 28 days and 2 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Vivaxin
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT07172724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172724.